DCP
UTHR icon

Distillate Capital Partners’s United Therapeutics UTHR Stock Holding History

Distillate Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6M Buy
+26,967
New +$15.2M 0.76% 77
2023
Q1 		– Sell
-46
Closed -$12.8K – 96
2022
Q4 		$12.8K Buy
+46
New +$11.6K 1.18% 10

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Distillate Capital Partners's UTHR Position: Q2 2026 in Review

Distillate Capital Partners opened a new position in United Therapeutics (UTHR) in Q2 2026: 26,967 shares worth $14.6M. The stake represents 0.76% of the portfolio and ranks #77 among its holdings. This is a return to the name: Distillate Capital Partners previously reported a position in UTHR as recently as Q4 2022.

Distillate Capital Partners first reported a position in UTHR in Q4 2022 and has held it in 2 quarters since. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Distillate Capital Partners held 26,967 shares of United Therapeutics worth $14.6M as of Q2 2026.
  • United Therapeutics was a new Distillate Capital Partners position in Q2 2026.
  • United Therapeutics made up 0.76% of Distillate Capital Partners's portfolio in Q2 2026, its #77 holding.
  • Distillate Capital Partners first reported a position in United Therapeutics in Q4 2022 and has held it in 2 quarters since.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Distillate Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.